TCRR News and Press, TCR2 Therapeutics Inc. From 01/07/20

CAMBRIDGE, Mass., Jan. 07, 2020 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer, today announced that Garry Menzel, Ph.D., President and Chief Exec...

This year was another crucial one for biotech thanks in large part to initial public offerings (IPOs), merger and acquisition (M&A) activity and niche therapeutic areas garnering attention. During the year, while the number of IPOs slowed in comparison to last year, some of the largest M...

TCR2 Therapeutics (NASDAQ: TCRR ): Q3 GAAP EPS of -$0.58 misses by $0.02 . More news on: TCR2 Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

CAMBRIDGE, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer, today announced financial results for the third quarter ended Sept...

Allogene Therapeutics (NASDAQ: ALLO ) initiated with Buy rating and $36 (24% upside) price target at Canaccord Genuity. More news on: Allogene Therapeutics, Inc., BioNTech SE, TCR2 Therapeutics Inc., Healthcare stocks news, Stocks on the move, , Read more ...

CAMBRIDGE, Mass., Oct. 09, 2019 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer, today announced the appointment of Angela Justice, Ph.D., as its f...

CAMBRIDGE, Mass., Sept. 27, 2019 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer, today announced that Ian Somaiya, Chief Financial Officer of TCR ...

CAMBRIDGE, Mass., Aug. 30, 2019 (GLOBE NEWSWIRE) -- TCR² Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer, today announced that Ian Somaiya, Chief Financial Officer ...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , iTunes...